No Data
Shareholders of Giant Bio (02367) will transfer their stocks from Goldman Sachs (Asia) Securities to Citibank, with a Market Cap of 2.607 billion HKD.
On April 23, the shareholders of Juzi Biotechnology (02367) transferred the stocks from Goldman Sachs (Asia) Securities to Citibank, with a market cap of 2.607 billion HKD, accounting for 3.28%.
Statistics on Capital Trend for Stock Connect (T+2) | April 24
Capital Trend of the Hong Kong Stock Connect | April 24th
Hong Kong stock market movement | Goliath Biotech (02367) rose more than 5% in the morning session, and the Shaanxi Provincial Drug Administration reported that multiple batches of Kefu Mei products did not detect EGF.
Giant Biotech (02367) rose more than 5% in early trading, as of the time of writing, it is up 4.44%, reported at 75.3 Hong Kong dollars, with a transaction amount of 0.422 billion Hong Kong dollars.
Giant Biogene Seeks HK$2.3 Billion in Top-Up Placement
Citi: Maintains Buy rating on Giant Bio (02367) with a Target Price of 78.1 HKD.
Giant Biotech announced on Thursday (17th) morning that it will place up to 35 million shares, representing 3.27% of the post-expansion share capital; the placement price is HKD 66.65, reflecting a discount of 9.5% compared to the closing price on the previous trading day (16th).
[Brokerage Focus] CITIC SEC indicates that China's Cosmetic market has entered a stable growth phase, but there are significant differences in the structure compared to Japan.
Jinwu Financial News | CITIC SEC states that during the century-long development of Japan's Cosmetic industry, economic and demand changes have progressed together. Before the 1980s, the industry expanded rapidly with economic growth, while after the 1980s, the industry slowed, and demand characteristics gave rise to structural opportunities. Among these: ① Product price differentiation, with high-end demand remaining stable in the long term, and the improvement of cost performance in mass products giving rise to effective cosmetics; ② Channels evolving driven by cost performance, with drugstores achieving low prices through pharmaceutical products. Currently, the environment of China's Cosmetic market shows certain similarities with Japan after the 1980s, with the market size also entering a steady growth phase, and exhibiting similarities to Japan in consumer preferences and product positioning.
